<story><title>EpiPen Maker Quietly Steers Effort That Could Protect Its Price</title><url>http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html</url></story><parent_chain></parent_chain><comment><author>bradleyjg</author><text>This whole drug company argument -- that the only thing that really matters is what end users pay as a co-pay or co-insurance and that no one should care what insurance companies (including governments) pay -- is so breathtakingly bad I can only imagine it is in bad faith. Where do they expect us to believe the institutional payments are coming from, out of thin air?</text></comment>
<story><title>EpiPen Maker Quietly Steers Effort That Could Protect Its Price</title><url>http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html</url></story><parent_chain></parent_chain><comment><author>maxerickson</author><text>Does the FDA have the authority to deny marketing approval for minor improvements?&lt;p&gt;Mylan pushed generics off the market by making a better cap or something, the FDA should just say no, that improvement is nice but it isn&amp;#x27;t enough to give you exclusive marketing rights. If you want to incorporate it into your product, license it to your competitors for cheap.</text></comment>